BALA CYNWYD, Pa., Sept. 12, 2022 (GLOBE NEWSWIRE) — Brodsky & Smith reminds investors of the following research. If you own stock and would like to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. You will not incur any costs or financial obligations.
Ra Medical Systems, Inc. (NYSE American – RMED)
Under the terms of the agreement, Ra Medical will merge with Catheter Precision, Inc. (“Catheter Precision”). The transaction is a reverse stock-for-stock merger in which all of Catheter Precision’s outstanding convertible debentures and equity interest will be exchanged for Ra Medical common stock and Catheter Precision options assumed by the Company. Catheter Precision shareholders are expected to own approximately 80% of the combined company and pre-merger Ra Medical shareholders are expected to own approximately 20% of the combined company. The investigation concerns whether the Ra Medical Board breached its fiduciary duties to shareholders by failing to conduct due process, including dilution for the company’s shareholders in the combined company.
For more information, see https://www.brodskysmith.com/cases/ra-medical-systems-inc-nyse-american-rmed/.
Brigham Minerals, Inc. (NYSE-MNRL)
Under the terms of the agreement, Brigham Minerals will partner with Sitio Royalties Corp. (“Sitio”) (NYSE – STR) to merge. Brigham Minerals stockholders will receive a fixed exchange ratio of 1,133 common shares of the combined company for each Brigham common share outstanding at the Closing Date. Upon closing of the transaction, Sitio shareholders will own approximately 54.0% and Brigham shareholders will own approximately 46.0% of the combined company on a fully diluted basis. The investigation concerns whether the Board of Directors of Brigham Minerals breached its fiduciary duties to shareholders by failing to conduct due process, including dilution…
